Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 137

Sort by

Sort Order Select

Journal Articles

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Blood (2024) 144 (21): 2169–2173.

https://doi.org/10.1182/blood.2024025409

Published: 2024

Journal Articles

Comparative Analysis of NGS and Digital PCR for Measurable Residual Disease Monitoring in Intensively Treated Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 6167.

https://doi.org/10.1182/blood-2024-203130

Published: 2024

Journal Articles

10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years

Blood (2024) 144 (Supplement 1): 218.

https://doi.org/10.1182/blood-2024-201058

Published: 2024

Journal Articles

HSP-CAR30, an Academic Memory-Enriched CART30, for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and CD30 + T Cell Lymphoma: Clinical Results of a Phase I/II Trial

Ana Carolina Caballero Gonzalez, Laura Escribà-Garcia, Cristina Ujaldón-Miró, Paula Pujol Fernández, Rosanna Montserrat-Torres, Eva Escudero-López, Irene García-Cadenas, Albert Esquirol, Maria Guardiola-Perello, Paola Jara-Bustamante, Rodrigo Martino, Jorge Sierra, Carmen Alvarez-Fernández, Javier Briones

Blood (2024) 144 (Supplement 1): 920.

https://doi.org/10.1182/blood-2024-210129

Published: 2024

Journal Articles

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Blood (2024) 144 (Supplement 1): 225.

https://doi.org/10.1182/blood-2024-204503

Published: 2024

Journal Articles

Efficacy and Safety of Reduced-Doses of Post-Transplant Cyclophosphamide in Matched Peripheral Blood Stem Cell Transplantation, a Multicenter Study

Yadith Karina Lopez-Garcia, Sara Redondo Velao, Andres Gomez-De Leon, Irene García-Cadenas, Héctor Alejandro Vaquera Alfaro, Perla R. Colunga-Pedraza, Albert Esquirol, César Homero Gutierrez-Aguirre, José Carlos Jaime-Pérez, Jorge Sierra, Olga Cantu, Javier Briones, David Gomez-Almaguer, Rodrigo Martino

Blood (2024) 144 (Supplement 1): 4898.

https://doi.org/10.1182/blood-2024-210332

Published: 2024

Journal Articles

Patients with Chronic Lymphocytic and Non-Hematologic Autoimmune Disorders Show Distinctive Clinical and Immune Alterations in Th17 and Treg Cells

Miguel Arguello De Tomas, Elionor Lynton-Pons, Nil Albiol, Jorge Sierra, Esther Moga, Carol Moreno

Blood (2024) 144 (Supplement 1): 3232.

https://doi.org/10.1182/blood-2024-198432

Published: 2024

Journal Articles

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Blood (2023) 142 (Supplement 1): 62.

https://doi.org/10.1182/blood-2023-183029

Published: 2023

Journal Articles

Ubtf tandem Duplications Define a Novel Subtype of Acute Myeloid Leukemia Associated with Younger Age, WT1 Mutations and HOXA9 Marked Overexpression

Helena Castellet, Guillermo Ramil López, Ana Garrido, Alícia Artigas-Baleri, Marta Pratcorona, Olga Salamero, Albert Cortés-Bullich, Susana Vives, Mar Tormo, Martin Mascaro Riera, David Gallardo, Josep Maria Marti Tutusaus, Antonio Garcia, Jorge Sierra, Jordi Esteve, Josep Nomdedeu

Blood (2023) 142 (Supplement 1): 6045.

https://doi.org/10.1182/blood-2023-186064

Published: 2023

Journal Articles

Bone Marrow WT1 mRNA Upregulation in Acute Myeloid Leukemia (AML) in Complete Molecular Remission (mCR): Understanding the Limitations and Advantages of WT1 As a Measurable Residual Disease (MRD) Target

Albert Esquirol, Yolanda Guillén, Elena Bussaglia, Vanesa Criado, Maite Carricondo, Pamela Acha, Manel Esteller, Jorge Sierra, Francesc Solé, Anna Bigas, Josep F Nomdedeu

Blood (2022) 140 (Supplement 1): 11786–11787.

https://doi.org/10.1182/blood-2022-166117

Published: 2022

Journal Articles

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Blood (2022) 140 (Supplement 1): 6053–6055.

https://doi.org/10.1182/blood-2022-165088

Published: 2022

Journal Articles

RAS Mutations in Adult Acute Myeloid Leukemia (AML). Frequency, Mutational Spectrum, and Identification of a Comutation Bias for KRAS K117 ( TET2 / ASXL1 )

Blood (2022) 140 (Supplement 1): 11821–11823.

https://doi.org/10.1182/blood-2022-164718

Published: 2022

Journal Articles

Phase 1 Clinical Trial of Memory-Enriched Academic HSP-CAR30 for the Treatment of Relapsed/Refractory Hodgkin Lymphoma and CD30 + T-Cell Lymphoma: Clinical and Biological Studies

Ana Carolina Carolina Caballero Gonzalez, Laura Escribà-García, Rosanna Montserrat, Eva Escudero-López, Paula Pujol-Fernández, Cristina Ujaldón-Miró, Irene García-Cadenas, Albert Esquirol, Rodrigo Martino, Jorge Sierra, Carmen Alvarez-Fernández, Javier Briones

Blood (2022) 140 (Supplement 1): 405–407.

https://doi.org/10.1182/blood-2022-167504

Published: 2022

Journal Articles

Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Blood (2022) 140 (Supplement 1): 4848–4850.

https://doi.org/10.1182/blood-2022-166166

Published: 2022

Journal Articles

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Blood (2022) 140 (12): 1345–1377.

https://doi.org/10.1182/blood.2022016867

Published: 2022

Journal Articles

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans-Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso-Ramos, Jorge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström-Lindberg, Gabriela S. Hobbs, Ronald Hoffman, Elias J. Jabbour, Jean-Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L.-C. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte Niemeyer, Olatoyosi M. Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P. Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A. Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi

Blood (2022) 140 (11): 1200–1228.

https://doi.org/10.1182/blood.2022015850

Published: 2022

Includes: Supplemental data

Journal Articles

Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Blood (2022) 139 (23): 3366–3375.

https://doi.org/10.1182/blood.2021011583

Published: 2022

Includes: Supplemental data

Journal Articles

Outcome of Human Umbilical Cord Blood Stem Cell Transplantation (CBT) for Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Versus Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Arnon Nagler, Myriam Labopin, Jan J. Cornelissen, Edouard Forcade, Patrice Chevallier, Nathalie Fegueux, Jorge Sierra, Hélène Labussière-Wallet, Jennifer Byrne, Thomas Cluzeau, Didier Blaise, Frédéric Baron, Annalisa Ruggeri, Mohamad Mohty, Deborah Desmier

Blood (2021) 138 (Supplement 1): 3964.

https://doi.org/10.1182/blood-2021-144827

Published: 2021

Journal Articles

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3 -Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Blood (2021) 138 (Supplement 1): 1303.

https://doi.org/10.1182/blood-2021-148129

Published: 2021

Journal Articles

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 4041.

https://doi.org/10.1182/blood-2021-149521

Published: 2021

NARROW

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Comparative Analysis of NGS and Digital PCR for Measurable Residual Disease Monitoring in Intensively Treated Acute Myeloid Leukemia Patients

10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years

HSP-CAR30, an Academic Memory-Enriched CART30, for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and CD30 + T Cell Lymphoma: Clinical Results of a Phase I/II Trial

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Efficacy and Safety of Reduced-Doses of Post-Transplant Cyclophosphamide in Matched Peripheral Blood Stem Cell Transplantation, a Multicenter Study

Patients with Chronic Lymphocytic and Non-Hematologic Autoimmune Disorders Show Distinctive Clinical and Immune Alterations in Th17 and Treg Cells

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Ubtf tandem Duplications Define a Novel Subtype of Acute Myeloid Leukemia Associated with Younger Age, WT1 Mutations and HOXA9 Marked Overexpression

Bone Marrow WT1 mRNA Upregulation in Acute Myeloid Leukemia (AML) in Complete Molecular Remission (mCR): Understanding the Limitations and Advantages of WT1 As a Measurable Residual Disease (MRD) Target

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

RAS Mutations in Adult Acute Myeloid Leukemia (AML). Frequency, Mutational Spectrum, and Identification of a Comutation Bias for KRAS K117 ( TET2 / ASXL1 )

Phase 1 Clinical Trial of Memory-Enriched Academic HSP-CAR30 for the Treatment of Relapsed/Refractory Hodgkin Lymphoma and CD30 + T-Cell Lymphoma: Clinical and Biological Studies

Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Outcome of Human Umbilical Cord Blood Stem Cell Transplantation (CBT) for Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Versus Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3 -Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only